Myriad Genetics Fourth Quarter 2024 Financial Earnings

02/24/2025 | 1:30pm PT / 4:30pm ET

View Presentation
Webcast Link

Events & Presentations

  • Leerink Global Healthcare Conference

    03/10/2025 | 11:20am PDT / 2:20pm EDT

    Watch the webcast

  • Raymond James - 2025 RJ 46th Annual Institutional Investor Conference

    03/04/2025 | 1:00pm PST / 4:00pm EST

    Watch the webcast

  • TD Cowen 45th Annual Health Care Conference

    03/04/2025 | 6:50am PST / 9:50am EST

    Watch the webcast
View all events

Financial Reports and Filings

Date Filing Title Downloads
03/26/2025 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/25/2025 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/25/2025 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/25/2025 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/25/2025 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/25/2025 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/25/2025 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/17/2025 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/17/2025 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/17/2025 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
View all filings

Latest News

Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools Thumbnail

Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools

Feb 27, 2025 | Products

Read more
Myriad Genetics Announces Senior Leadership Transition Thumbnail

Myriad Genetics Announces Senior Leadership Transition

Feb 24, 2025 | Corporate | Financial

Read more
Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth Thumbnail

Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth

Feb 24, 2025 | Corporate | Financial

Read more
View all news releases

Quality, Innovation and Corporate Responsibility Report

Myriad Genetics has a strong commitment to operational excellence, innovation and being a good corporate partner. Our dedication to these important issues serve as the foundation to achieving our mission of advancing health and well-being for all.

Learn more about the actions we’re taking in quality, innovation, and corporate responsibility.

Read our QICR report
“Quality, innovation and corporate responsibility are at the heart of what we do at Myriad Genetics. This report reflects our progress on how we are making genetic testing more accessible, helping patients take more control of their health, and enabling providers to better prevent and treat disease."

— Paul J. Diaz
President and CEO, Myriad Genetics

Quality, Innovation and Corporate Responsibility Report

Myriad Genetics has a strong commitment to operational excellence, innovation and being a good corporate partner. Our dedication to these important issues serve as the foundation to achieving our mission of advancing health and well-being for all.

Learn more about the actions we’re taking in quality, innovation, and corporate responsibility.

Read our QICR report
“Quality, innovation and corporate responsibility are at the heart of what we do at Myriad Genetics. This report reflects our progress on how we are making genetic testing more accessible, helping patients take more control of their health, and enabling providers to better prevent and treat disease."

— Paul J. Diaz
President and CEO, Myriad Genetics